Trials
2 active
4 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “5 mg/kg or 10 mg/kg IV infusion over 60 minutes on Day 1, 8, 15 and 21 of each 28 day cycle”In the company’s words, NCT06038578 on ClinicalTrials.gov
- Tested for
- Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor, Melanoma
- Main trialPhase 2
- “This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma.”In the company’s words, NCT06038578 on ClinicalTrials.gov
Other drugs for Gastric Adenocarcinoma
- CAM2029Camurus AB · Phase 3
- Disitamab VedotinRemeGen · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
- M108FutureGen Biopharmaceutical (Beijing) Co., Ltd · Phase 3
- RilvegostomigAstraZeneca · Phase 3
Coming up2
- 31 Oct 2027Phase 2 trial completes · ClinicalTrials.gov
- 31 Mar 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Oct 2027 | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | |
| Phase 1/2Recruiting | 31 Mar 2028 | A Study of TRK-950 in Patients With Advanced Solid Tumors | |
| Phase 1Completed | 16 Sep 2019 | A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors | |
| Phase 1Completed | 16 Jul 2026 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026